DiaMedica Therapeutics (DMAC) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS

DiaMedica Therapeutics (NASDAQ:DMAC) released its earnings results on Monday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05), Morningstar.com reports.

Shares of NASDAQ:DMAC opened at $3.11 on Wednesday. DiaMedica Therapeutics has a 52-week low of $2.46 and a 52-week high of $4.80.

A number of large investors have recently made changes to their positions in DMAC. BlackRock Inc. bought a new position in DiaMedica Therapeutics in the first quarter worth approximately $47,000. Worth Venture Partners LLC bought a new position in DiaMedica Therapeutics in the fourth quarter worth approximately $377,000. Finally, Wexford Capital LP bought a new position in DiaMedica Therapeutics in the fourth quarter worth approximately $1,382,000. Institutional investors and hedge funds own 8.67% of the company’s stock.



DMAC has been the subject of several recent analyst reports. Dougherty & Co initiated coverage on DiaMedica Therapeutics in a research note on Tuesday, April 30th. They set a “buy” rating and a $8.00 target price for the company. Lake Street Capital initiated coverage on DiaMedica Therapeutics in a research note on Tuesday, March 5th. They set a “buy” rating and a $9.00 target price for the company.

COPYRIGHT VIOLATION NOTICE: “DiaMedica Therapeutics (DMAC) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://dakotafinancialnews.com/2019/05/15/diamedica-therapeutics-dmac-issues-quarterly-earnings-results-misses-expectations-by-0-05-eps.html.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Read More: What is the Ex-Dividend Date in Investing?

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.